Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19

Norihito Omote, Yoshihiro Kanemitsu, Takahiro Inoue, Toshiyuki Yonezawa, Takuji Ichihashi, Yuichiro Shindo, Koji Sakamoto, Akira Ando, Atsushi Suzuki, Akio Niimi, Satoru Ito, Kazuyoshi Imaizumi, Naozumi Hashimoto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We herein report a case of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) triggered by COVID-19. An 87-year-old woman tested positive for COVID-19 on a polymerase chain reaction test, and computed tomography revealed ground-glass opacity (GGO) superimposed on a background pattern consistent with usual interstitial pneumonia. Considering these data, we diagnosed her with AE-IPF. She experienced worsening of dyspnea and expansion of the GGO. Therefore, we introduced high-dose steroids (methylprednisolone 250 mg/day for 3 days). After the treatment, the pulmonary infiltrates improved. She was discharged from our hospital without severe disability. High-dose steroids can be a viable treatment option for AE-IPF triggered by COVID-19.

Original languageEnglish
Pages (from-to)233-236
Number of pages4
JournalInternal Medicine
Volume61
Issue number2
DOIs
Publication statusPublished - 2022

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19'. Together they form a unique fingerprint.

Cite this